Immunogenicity of a synthetic vaccine based on Plasmodium vivax Duffy binding protein region II

Clinical and Vaccine Immunology

Volumn 21, Issue 9, 2014, Pages 1215-1223

  Ntumngia, Francis B ^a   Barnes, Samantha J ^a   McHenry, Amy M ^a,b   George, Miriam T ^a   Schloegel, Jesse ^a,c   Adams, John H ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b Southwestern Adventist University   (United States)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DUFFY BINDING PROTEIN; DUFFY BINDING PROTEIN REGION II VACCINE; MALARIA VACCINE; RECOMBINANT VACCINE; UNCLASSIFIED DRUG; CELL SURFACE RECEPTOR; DUFFY ANTIGEN BINDING PROTEIN, PLASMODIUM; PARASITE ANTIGEN; PROTOZOAL PROTEIN; PROTOZOON ANTIBODY; RECOMBINANT PROTEIN;

ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG SPECIFICITY; DRUG SYNTHESIS; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PLASMODIUM VIVAX; PRIORITY JOURNAL; ANIMAL; BAGG ALBINO MOUSE; BLOOD; CELL PROLIFERATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; IMMUNOLOGY; MALARIA; MONONUCLEAR CELL; PARASITOLOGY; SPLEEN; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; CELL PROLIFERATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; LEUKOCYTES, MONONUCLEAR; MALARIA; MALARIA VACCINES; MICE, INBRED BALB C; PLASMODIUM VIVAX; PROTOZOAN PROTEINS; RECEPTORS, CELL SURFACE; RECOMBINANT PROTEINS; SPLEEN; TREATMENT OUTCOME; VACCINES, SYNTHETIC;

EID: 84928818638     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00205-14     Document Type: Article

References (62)

1. Branch OH, Udhayakumar V, Hightower AW, Oloo AJ, Hawley WA, Nahlen BL, Bloland PB, Kaslow DC, Lal AA. 1998. A longitudinal investigation of IgG and IgM antibody responses to the merozoite surface protein-1 19-kiloDalton domain of Plasmodium falciparum in pregnant women and infants: associations with febrile illness, parasitemia, and anemia. Am. J. Trop. Med. Hyg. 58:211-219. (Pubitemid 28096229)
2. King CL, Michon P, Shakri AR, Marcotty A, Stanisic D, Zimmerman PA, Cole-Tobian JL, Mueller I, Chitnis CE. 2008. Naturally acquired Duffy-binding protein-specific binding inhibitory antibodies confer protection from blood-stage Plasmodium vivax infection. Proc. Natl. Acad. Sci. U. S. A. 105:8363-8368. http://dx.doi.org/10.1073/pnas.0800371105. (Pubitemid 351904761)
3. Cohen S, McGregor IA, Carrington S. 1961. Gamma-globulin and acquired immunity to human malaria. Nature 192:733-737. http://dx.doi.org/10.1038/ 192733a0.
4. Clyde DF, Most H, McCarthy VC, Vanderberg JP. 1973. Immunization of man against sporozoite-induced falciparum malaria. Am. J. Med. Sci. 266:169-177. http://dx.doi.org/10.1097/00000441-197309000-00002.
5. Grimberg BT, Udomsangpetch R, Xainli J, McHenry A, Panichakul T, Sattabongkot J, Cui L, Bockarie M, Chitnis C, Adams J, Zimmerman PA, King CL. 2007. Plasmodium vivax invasion of human erythrocytes inhibited by antibodies directed against the Duffy binding protein. PLoS Med. 4(12):e337. http://dx.doi.org/10.1371/journal.pmed.0040337.
6. Singh AP, Puri SK, Chitnis CE. 2002. Antibodies raised against receptor-binding domain of Plasmodium knowlesi Duffy binding protein inhibit erythrocyte invasion. Mol. Biochem. Parasitol. 121:21-31. http://dx.doi.org/10. 1016/S0166-6851(02)00017-8. (Pubitemid 34457831)
7. Pattnaik P, Shakri AR, Singh S, Goel S, Mukherjee P, Chitnis CE. 2007. Immunogenicity of a recombinant malaria vaccine based on receptor binding domain of Plasmodium falciparum EBA-175. Vaccine 25:806-813. http://dx.doi.org/10. 1016/j.vaccine.2006.09.048. (Pubitemid 44856130)
8. Woehlbier U, Epp C, Hackett F, Blackman MJ, Bujard H. 2010. Antibodies against multiple merozoite surface antigens of the human malaria parasite Plasmodium falciparum inhibit parasite maturation and red blood cell invasion. Malar. J. 9:77. http://dx.doi.org/10.1186/1475-2875-9-77.
9. Adams JH, Sim BK, Dolan SA, Fang X, Kaslow DC, Miller LH. 1992. A family of erythrocyte binding proteins of malaria parasites. Proc. Natl. Acad. Sci. U. S. A. 89:7085-7089. http://dx.doi.org/10.1073/pnas.89.15.7085.
10. Barnwell JW, Wertheimer SP. 1989. Plasmodium vivax: merozoite antigens, the Duffy blood group, and erythrocyte invasion. Prog. Clin. Biol. Res. 313:1-11.
11. Dvorak JA, Miller LH, Whitehouse WC, Shiroishi T. 1975. Invasion of erythrocytes by malaria merozoites. Science 187:748-750. http://dx.doi.org/10. 1126/science.803712.
12. Aikawa M, Miller LH, Johnson J, Rabbege J. 1978. Erythrocyte entry by malarial parasites. A moving junction between erythrocyte and parasite. J. Cell Biol. 77:72-82. (Pubitemid 8321757)
13. Miller LH, Mason SJ, Clyde DF, McGinniss MH. 1976. The resistance factor to Plasmodium vivax in blacks. The Duffy-blood-group genotype, FyFy. N. Engl. J. Med. 295:302-304.
14. Miller LH, Mason SJ, Dvorak JA, McGinniss MH, Rothman IK. 1975. Erythrocyte receptors for (Plasmodium knowlesi) malaria: Duffy blood group determinants. Science 189:561-563. http://dx.doi.org/10.1126/science.1145213.
15. Xainli J, Cole-Tobian JL, Baisor M, Kastens W, Bockarie M, Yazdani SS, Chitnis CE, Adams JH, King CL. 2003. Epitope-specific humoral immunity to Plasmodium vivax Duffy binding protein. Infect. Immun. 71:2508-2515. http://dx.doi.org/10.1128/IAI.71.5.2508-2515.2003. (Pubitemid 36519863)
16. Cerávolo IP, Bruna-Romero O, Braga EM, Fontes CJ, Brito CF, Souza JM, Krettli AU, Adams JH, Carvalho LH. 2005. Anti-Plasmodium vivax Duffy binding protein antibodies measure exposure to malaria in the Brazilian Amazon. Am. J. Trop. Med. Hyg. 72:675-681.
17. Chootong P, Ntumngia FB, VanBuskirk KM, Xainli J, Cole-Tobian JL, Campbell CO, Fraser TS, King CL, Adams JH. 2010. Mapping epitopes of the Plasmodium vivax Duffy binding protein with naturally acquired inhibitory antibodies. Infect. Immun. 78:1089-1095. http://dx.doi.org/10.1128/IAI.01036-09.
18. Dutta S, Daugherty JR, Ware LA, Lanar DE, Ockenhouse CF. 2000. Expression, purification and characterization of a functional region of the Plasmodium vivax Duffy binding protein. Mol. Biochem. Parasitol. 109: 179-184. http://dx.doi.org/10.1016/S0166-6851(00)00244-9. (Pubitemid 30665415)
19. Michon PA, Arevalo-Herrera M, Fraser T, Herrera S, Adams JH. 1998. Serologic responses to recombinant Plasmodium vivax Duffy binding protein in a Colombian village. Am. J. Trop. Med. Hyg. 59:597-599. (Pubitemid 28480718)
20. Yazdani SS, Shakri AR, Chitnis CE. 2004. A high cell density fermentation strategy to produce recombinant malarial antigen in E. coli. Biotechnol. Lett. 26:1891-1895. http://dx.doi.org/10.1007/s10529-004-6040-4. (Pubitemid 40181260)
21. Michon P, Fraser T, Adams JH. 2000. Naturally acquired and vaccine-elicited antibodies block erythrocyte cytoadherence of the Plasmodium vivax Duffy binding protein. Infect. Immun. 68:3164-3171. http://dx.doi.org/10. 1128/IAI.68.6.3164-3171.2000. (Pubitemid 30340405)
22. VanBuskirk KM, Sevova E, Adams JH. 2004. Conserved residues in the Plasmodium vivax Duffy-binding protein ligand domain are critical for erythrocyte receptor recognition. Proc. Natl. Acad. Sci. U. S. A. 101: 15754-15759. http://dx.doi.org/10.1073/pnas.0405421101. (Pubitemid 39473560)
23. Chitnis CE, Chaudhuri A, Horuk R, Pogo AO, Miller LH. 1996. The domain on the Duffy blood group antigen for binding Plasmodium vivax and P. knowlesi malarial parasites to erythrocytes. J. Exp. Med. 184:1531-1536. http://dx.doi.org/10.1084/jem.184.4.1531. (Pubitemid 26354709)
24. Singh SK, Hora R, Belrhali H, Chitnis CE, Sharma A. 2006. Structural basis for Duffy recognition by the malaria parasite Duffy-binding-like domain. Nature 439:741-744. http://dx.doi.org/10.1038/nature04443. (Pubitemid 43237622)
25. Batchelor JD, Zahm JA, Tolia NH. 2011. Dimerization of Plasmodium vivax DBP is induced upon receptor binding and drives recognition of DARC. Nat. Struct. Mol. Biol. 18:908-914. http://dx.doi.org/10.1038/nsmb.2088.
26. Ampudia E, Patarroyo MA, Patarroyo ME, Murillo LA. 1996. Genetic polymorphism of the Duffy receptor binding domain of Plasmodium vivax in Colombian wild isolates. Mol. Biochem. Parasitol. 78:269-272. http://dx.doi.org/10.1016/S0166-6851(96)02611-4.
27. Hans D, Pattnaik P, Bhattacharyya A, Shakri AR, Yazdani SS, Sharma M, Choe H, Farzan M, Chitnis CE. 2005. Mapping binding residues in the Plasmodium vivax domain that binds Duffy antigen during red cell invasion. Mol. Microbiol. 55:1423-1434. http://dx.doi.org/10.1111/j.1365-2958.2005.04484.x. (Pubitemid 40342070)
28. Ranjan A, Chitnis CE. 1999. Mapping regions containing binding residues within functional domains of Plasmodium vivax and Plasmodium knowlesi erythrocyte-binding proteins. Proc. Natl. Acad. Sci. U. S. A. 96: 14067-14072. http://dx.doi.org/10.1073/pnas.96.24.14067.
29. Tsuboi T, Kappe SH, al-Yaman F, Prickett MD, Alpers M, Adams JH. 1994. Natural variation within the principal adhesion domain of the Plasmodium vivax Duffy binding protein. Infect. Immun. 62:5581-5586. (Pubitemid 24365004)
30. Cole-Tobian J, King CL. 2003. Diversity and natural selection in Plasmodium vivax Duffy binding protein gene. Mol. Biochem. Parasitol. 127: 121-132. http://dx.doi.org/10.1016/S0166-6851(02)00327-4. (Pubitemid 36369687)
31. Ntumngia FB, McHenry AM, Barnwell JW, Cole-Tobian J, King CL, Adams JH. 2009. Genetic variation among Plasmodium vivax isolates adapted to non-human primates and the implication for vaccine development. Am. J. Trop. Med. Hyg. 80:218-227.
32. Xainli J, Adams JH, King CL. 2000. The erythrocyte binding motif of Plasmodium vivax Duffy binding protein is highly polymorphic and functionally conserved in isolates from Papua New Guinea. Mol. Biochem. Parasitol. 111: 253-260. http://dx.doi.org/10.1016/S0166-6851(00)00315-7. (Pubitemid 32121669)
33. Cole-Tobian JL, Michon P, Biasor M, Richards JS, Beeson JG, Mueller I, King CL. 2009. Strain-specific Duffy binding protein antibodies correlate with protection against infection with homologous compared to heterologous Plasmodium vivax strains in Papua New Guinean children. Infect. Immun. 77:4009-4017. http://dx.doi.org/10.1128/IAI.00158-09.
34. Welsh RM, Fujinami RS. 2007. Pathogenic epitopes, heterologous immunity and vaccine design. Nat. Rev. Microbiol. 5:555-563. http://dx.doi.org/10.1038/ nrmicro1709. (Pubitemid 46925383)
35. Tobin GJ, Trujillo JD, Bushnell RV, Lin G, Chaudhuri AR, Long J, Barrera J, Pena L, Grubman MJ, Nara PL. 2008. Deceptive imprinting and immune refocusing in vaccine design. Vaccine 26:6189-6199. http://dx.doi.org/10.1016/j.vaccine. 2008.09.080.
36. Ntumngia FB, Adams JH. 2012. Design and immunogenicity of a novel synthetic antigen based on the ligand domain of the Plasmodium vivax Duffy binding protein. Clin. Vaccine Immunol. 19:30-36. http://dx.doi.org/10.1128/CVI. 05466-11.
37. Ntumngia FB, Schloegel J, McHenry AM, Barnes SJ, George MT, Kennedy S, Adams JH. 2013. Immunogenicity of single versus mixed allele vaccines of Plasmodium vivax Duffy binding protein region II. Vaccine 31:4382-4388. http://dx.doi.org/10.1016/j.vaccine.2013.07.002.
38. Cavanagh DR, Dodoo D, Hviid L, Kurtzhals JA, Theander TG, Akanmori BD, Polley S, Conway DJ, Koram K, McBride JS. 2004. Antibodies to the N-terminal block 2 of Plasmodium falciparum merozoite surface protein 1 are associated with protection against clinical malaria. Infect. Immun. 72:6492-6502. http://dx.doi.org/10.1128/IAI.72.11.6492-6502.2004. (Pubitemid 39425430)
39. Conway DJ, Cavanagh DR, Tanabe K, Roper C, Mikes ZS, Sakihama N, Bojang KA, Oduola AM, Kremsner PG, Arnot DE, Greenwood BM, McBride JS. 2000. A principal target of human immunity to malaria identified by molecular population genetic and immunological analyses. Nat. Med. 6:689-692. http://dx.doi.org/10. 1038/76272. (Pubitemid 30398794)
40. Osier FH, Fegan G, Polley SD, Murungi L, Verra F, Tetteh KK, Lowe B, Mwangi T, Bull Thomas PCAW, Cavanagh DR, McBride JS, Lanar DE, Mackinnon MJ, Conway DJ, Marsh K. 2008. Breadth and magnitude of antibody responses to multiple Plasmodium falciparum merozoite antigens are associated with protection from clinical malaria. Infect. Immun. 76:2240-2248. http://dx.doi.org/10.1128/ IAI.01585-07. (Pubitemid 351656161)
41. Cole-Tobian JL, Cortes A, Baisor M, Kastens W, Xainli J, Bockarie M, Adams JH, King CL. 2002. Age-acquired immunity to a Plasmodium vivax invasion ligand, the Duffy binding protein. J. Infect. Dis. 186:531- 539. http://dx.doi.org/10.1086/341776.
42. Fraser T, Michon P, Barnwell JW, Noe AR, Al-Yaman F, Kaslow DC, Adams JH. 1997. Expression and serologic activity of a soluble recombinant Plasmodium vivax Duffy binding protein. Infect. Immun. 65:2772-2777. (Pubitemid 27264107)
43. Cerávolo IP, Sanchez BA, Sousa TN, Guerra BM, Soares IS, Braga EM, McHenry AM, Adams JH, Brito CF, Carvalho LH. 2009. Naturally acquired inhibitory antibodies to Plasmodium vivax Duffy binding protein are short-lived and allele-specific following a single malaria infection. Clin. Exp. Immunol. 156:502-510. http://dx.doi.org/10.1111/j.1365-2249.2009.03931.x.
44. Deloron P, Chougnet C. 1992. Is immunity to malaria really short-lived? Parasitol. Today 8:375-378. http://dx.doi.org/10.1016/0169-4758(92)90174-Z.
45. Langhorne J, Ndungu FM, Sponaas AM, Marsh K. 2008. Immunity to malaria: more questions than answers. Nat. Immunol. 9:725-732. http://dx.doi.org/10.1038/ ni.f.205. (Pubitemid 351859155)
46. Snow RW, Marsh K. 2002. The consequences of reducing transmission of Plasmodium falciparum in Africa. Adv. Parasitol. 52:235-264. http://dx.doi.org/10.1016/S0065-308X(02)52013-3. (Pubitemid 36069925)
47. Bejon P, Mwacharo J, Kai O, Mwangi T, Milligan P, Todryk S, Keating S, Lang T, Lowe B, Gikonyo C, Molyneux C, Fegan G, Gilbert SC, Peshu N, Marsh K, Hill AV. 2006. A phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya. PLoS Clin. Trials 1(6):e29. http://dx.doi.org/10.1371/journal.pctr.0010029.
48. Ntumngia FB, Schloegel J, Barnes SJ, McHenry AM, Singh S, King CL, Adams JH. 2012. Conserved and variant epitopes of Plasmodium vivax Duffy binding protein as targets of inhibitory monoclonal antibodies. Infect. Immun. 80:1203-1208. http://dx.doi.org/10.1128/IAI.05924-11.
49. Tran TM, Moreno A, Yazdani SS, Chitnis CE, Barnwell JW, Galinski MR. 2005. Detection of a Plasmodium vivax erythrocyte binding protein by flow cytometry. Cytometry A 63:59-66. http://dx.doi.org/10.1002/cyto.a.20098. (Pubitemid 40194280)
50. Singh S, Pandey K, Chattopadhayay R, Yazdani SS, Lynn A, Bharadwaj A, Ranjan A, Chitnis C. 2001. Biochemical, biophysical, and functional characterization of bacterially expressed and refolded receptor binding domain of Plasmodium vivax Duffy-binding protein. J. Biol. Chem. 276:17111-17116. http://dx.doi.org/10.1074/jbc.M101531200.
51. Mullen GE, Giersing BK, Ajose-Popoola O, Davis HL, Kothe C, Zhou H, Aebig J, Dobrescu G, Saul A, Long CA. 2006. Enhancement of functional antibody responses to AMA1-C1/Alhydrogel, a Plasmodium falciparum malaria vaccine, with CpG oligodeoxynucleotide. Vaccine 24:2497-2505. http://dx.doi.org/10.1016/j. vaccine.2005.12.034. (Pubitemid 43290379)
52. Alaro JR, Lynch MM, Burns JM, Jr. 2010. Protective immune responses elicited by immunization with a chimeric blood-stage malaria vaccine persist but are not boosted by Plasmodium yoelii challenge infection. Vaccine 28:6876-6884. http://dx.doi.org/10.1016/j.vaccine.2010.08.018.
53. Deng YH, Sun Z, Yang XL, Bao L. 2010. Improved immunogenicity of recombinant Mycobacterium bovis bacillus Calmette-Guerin strains expressing fusion protein Ag85A-ESAT-6 of Mycobacterium tuberculosis. Scand. J. Immunol. 72:332-338. http://dx.doi.org/10.1111/j.1365-3083.2010.02444.x.
54. Michon P, Woolley I, Wood EM, Kastens W, Zimmerman PA, Adams JH. 2001. Duffy-null promoter heterozygosity reduces DARC expression and abrogates adhesion of the P. vivax ligand required for blood-stage infection. FEBS Lett. 495:111-114. http://dx.doi.org/10.1016/S0014-5793(01)02370-5. (Pubitemid 32367983)
55. Chitnis CE, Miller LH. 1994. Identification of the erythrocyte binding domains of Plasmodium vivax and Plasmodium knowlesi proteins involved in erythrocyte invasion. J. Exp. Med. 180:497-506. http://dx.doi.org/10.1084/jem. 180.2.497. (Pubitemid 24224126)
56. VanBuskirk KM, Cole-Tobian JL, Baisor M, Sevova ES, Bockarie M, King CL, Adams JH. 2004. Antigenic drift in the ligand domain of Plasmodium vivax Duffy binding protein confers resistance to inhibitory antibodies. J. Infect. Dis. 190:1556-1562. http://dx.doi.org/10.1086/424852. (Pubitemid 39411003)
57. Remarque EJ, Roestenberg M, Younis S, Walraven V, van der Werff N, Faber BW, Leroy O, Sauerwein R, Kocken CH, Thomas AW. 2012. Humoral immune responses to a single allele PfAMA1 vaccine in healthy malaria-naive adults. PLoS One 7(6):e38898. http://dx.doi.org/10.1371/journal.pone.0038898.
58. Hodder AN, Crewther PE, Anders RF. 2001. Specificity of the protective antibody response to apical membrane antigen 1. Infect. Immun. 69:3286-3294. http://dx.doi.org/10.1128/IAI.69.5.3286-3294.2001. (Pubitemid 32332227)
59. Kusi KA, Faber BW, Thomas AW, Remarque EJ. 2009. Humoral immune response to mixed PfAMA1 alleles; multivalent PfAMA1 vaccines induce broad specificity. PLoS One 4(12):e8110. http://dx.doi.org/10.1371/journal.pone.0008110.
60. Kusi KA, Faber BW, Riasat V, Thomas AW, Kocken CH, Remarque EJ. 2010. Generation of humoral immune responses to multi-allele PfAMA1 vaccines; effect of adjuvant and number of component alleles on the breadth of response. PLoS One 5(11):e15391. http://dx.doi.org/10.1371/journal.pone.0015391.
61. Kaech SM, Wherry EJ, Ahmed R. 2002. Effector and memory T-cell differentiation: implications for vaccine development. Nat. Rev. Immunol. 2:251-262. http://dx.doi.org/10.1038/nri778. (Pubitemid 37323225)
62. Xainli J, Baisor M, Kastens W, Bockarie M, Adams JH, King CL. 2002. Age-dependent cellular immune responses to Plasmodium vivax Duffy binding protein in humans. J. Immunol. 169:3200-3207. http://dx.doi.org/10.4049/ jimmunol.169.6.3200. (Pubitemid 35013166)